Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

被引：0
|
作者：
Maysa M. Abu-Khalaf
Vinni Juneja
Gina G. Chung
Michael P. DiGiovanna
Rebecca Sipples
Meghan McGurk
Daniel Zelterman
Bruce Haffty
Michael Reiss
Frans J. Wackers
Forrester A. Lee
Barbara A. Burtness
机构：
[1] Yale University School of Medicine,Department of Internal Medicine, Section of Medical Oncology
[2] Yale Cancer Center,Division of Biostatistics
[3] Yale University,Department of Radiation Oncology, UMDNJ
[4] Cancer Institute of New Jersey,Robert Wood Johnson Medical School
[5] Cancer Institute of New Jersey,Department of Internal Medicine, Section of Medical Oncology, UMDNJ
[6] Yale University School of Medicine,Robert Wood Johnson Medical School
[7] Division of Medical Sciences,Department of Internal Medicine, Section of Cardiology
[8] Fox Chase Cancer Center,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2007年 / 104卷
关键词：
Anthracycline; Adjuvant therapy; Breast cancer; Cardiac dysfunction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：341 / 349
页数：8
相关论文
共 50 条
  • [1] Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
    Abu-Khalaf, Maysa M.
    Juneja, Vinni
    Chung, Gina G.
    DiGiovanna, Michael P.
    Sipples, Rebecca
    McGurk, Meghan
    Zelterman, Daniel
    Haffty, Bruce
    Reiss, Michael
    Wackers, Frans J.
    Lee, Forrester A.
    Burtness, Barbara A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 104 (03) : 341 - 349
  • [2] Late adriamycin-related cardiotoxicity of dose-dense and intense sequential doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
    Abu-Khalaf, M
    Juneja, V
    Chung, G
    DiGiovanna, M
    Wackers, F
    Lee, F
    Burtness, B
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S109 - S110
  • [3] Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer
    Kelemen, Gyoengyi
    Uhercsak, Gabriella
    Ormandi, Katalin
    Eller, Jozsef
    Thurzo, Laszlo
    Kahan, Zsuzsanna
    [J]. ONCOLOGY, 2010, 78 (3-4) : 271 - 273
  • [4] Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting
    Burtness, B
    Windsor, S
    Holston, B
    DiStasio, S
    Staugaard-Hahn, C
    Abrantes, J
    Kneuper-Hall, R
    Farber, L
    Orell, J
    Bober-Sorcinelli, K
    Haffty, BG
    Reiss, M
    [J]. CANCER JOURNAL, 1999, 5 (04): : 224 - 229
  • [5] Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
    Hudis, C
    Seidman, A
    Baselga, J
    Raptis, G
    Lebwohl, D
    Gilewski, T
    Moynahan, M
    Sklarin, N
    Fennelly, D
    Crown, JPA
    Surbone, A
    Uhlenhopp, M
    Riedel, E
    Yao, TJ
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 93 - 100
  • [6] Long-Term Cardiac Safety and Outcomes of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab With and Without Lapatinib in Patients With Early Breast Cancer
    Morris, Patrick G.
    Iyengar, Neil M.
    Patil, Sujata
    Chen, Carol
    Abbruzzi, Alyson
    Lehman, Robert
    Steingart, Richard
    Oeffinger, Kevin C.
    Lin, Nancy
    Moy, Beverley
    Come, Steven E.
    Winer, Eric P.
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    [J]. CANCER, 2013, 119 (22) : 3943 - 3951
  • [7] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
    Fountzilas, G
    Papadimitriou, C
    Aravantinos, G
    Nicolaides, C
    Stathopoulos, G
    Bafaloukos, D
    Kalofonos, H
    Ekonomopoulos, T
    Skarlos, D
    Pavlidis, N
    Dimopoulos, AM
    [J]. ONCOLOGY, 2001, 60 (03) : 214 - 220
  • [8] Dose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: a pilot study.
    Link, JS
    Forsthoff, CA
    Ibarra, J
    Rogers, LW
    Magy, F
    Maya, KA
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S59 - S60
  • [9] Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
    Pippen, John
    Paul, Devchand
    Vukelja, Svetislava
    Clawson, Alicia
    Iglesias, Jose
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) : 825 - 831
  • [10] Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
    John Pippen
    Devchand Paul
    Svetislava Vukelja
    Alicia Clawson
    Jose Iglesias
    [J]. Breast Cancer Research and Treatment, 2011, 130 : 825 - 831
12345